9885 (9885) Fair Value & Analysis

Healthcare · Market cap HK$3.1B

9 9885 9885 · HK

PriceHK$4.54

Fair ValueHK$4.35

Upside-4.2%

Quality42/100

Watch 9885 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.32 – HK$5.44

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price +28.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.05 – HK$11.96 · fair‑value band HK$3.32 – HK$5.44 · the HK$4.54 price screens above the HK$4.35 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9885 (9885) currently trades at HK$4.54, while our model-based Fair Value estimate is HK$4.35 — implying the stock looks roughly 4.2% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 9885 generated revenue of HK$21.0B at a net margin of 0.7%. Revenue grew 22.4% year over year. It earns a return on equity of 6.3%. Net debt stands at HK$423M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$21.0B

Revenue growth (YoY) +22.4%

Net margin 0.7%

Return on equity 6.3%

Free cash flow HK$619M FY2025

P/E ratio 18.2

More key figures

Operating margin 0.2%

EPS (TTM) HK$0.1100

Dividend yield 2.6%

EPS growth (YoY) +769%

Net debt HK$423M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

9885 reported revenue of HK$21.0B in FY2025 versus HK$10.1B in FY2021, a compound +20.1%/yr. Reported net income was HK$153M in FY2025.

Revenue +20.1%/yr

FY21 HK$10.1B

FY22 HK$14.3B

FY23 HK$17.0B

FY24 HK$17.9B

FY25 HK$21.0B

Net income

FY21 −HK$502M

FY22 −HK$1.5B

FY23 −HK$3.2B

FY24 HK$30.0M

FY25 HK$153M

Is 9885 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIF	$5.85	$7.13	+22%
6618 6618	HK$34.16	HK$33.08	-3%
Alibaba Health Information Technology Limited ALBBY	$8.27	$6.61	-20%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.46	R$16.13	-8%
Yifeng Pharmacy Chain Co 603939	¥20.91	¥22.00	+5%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 9885 (9885) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$4.35 versus a price of HK$4.54 — about −4% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 9885?

Our model-based fair value for 9885 is HK$4.35 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$4.54.

What is the quality score of 9885?

9885 has a Quality Score of 42/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 9885 (9885)?

9885 reported trailing-twelve-month revenue of about HK$21.0B (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 9885?

The net profit margin of 9885 is about 0.7%, meaning it keeps roughly 0.7% of revenue as net income. Based on the latest reported figures.

Does 9885 pay a dividend?

9885 currently shows a dividend yield of about 2.55% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.